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Abstract
Background: Nitric oxide (NO) has been noted to produce ischemic preconditioning (IPC)-mediated
cardioprotection. Caveolin is a negative regulator of NO, which inhibits endothelial nitric oxide synthase (eNOS) by
making caveolin-eNOS complex. The expression of caveolin is increased during diabetes mellitus (DM). The present
study was designed to investigate the involvement of caveolin in attenuation of the cardioprotective effect of IPC
during DM in rat.
Methods: Experimental DM was induced by single dose of streptozotocin (50 mg/Kg, i.p,) and animals were used
for experiments four weeks later. Isolated heart was mounted on Langendorff’s apparatus, and was subjected to 30
min of global ischemia and 120 min of reperfusion. IPC was given by four cycles of 5 min of ischemia and 5 min
of reperfusion with Kreb’s-Henseleit solution (K-H). Extent of injury was measured in terms of infarct size by
triphenyltetrazolium chloride (TTC) staining, and release of lactate dehydrogenase (LDH) and creatin kinase-MB (CK-
MB) in coronary effluent. The cardiac release of NO was noted by measuring the level of nitrite in coronary
effluent.
Results: IPC- induced cardioprotection and release of NO was significantly decreased in diabetic rat heart. Pre-
treatment of diabetic rat with daidzein (DDZ) a caveolin inhibitor (0.2 mg/Kg/s.c), for one week, significantly
increased the release of NO and restored the attenuated cardioprotective effect of IPC. Also perfusion of sodium
nitrite (10 μM/L), a precursor of NO, significantly restored the lost effect of IPC, similar to daidzein in diabetic rat.
Administration of 5-hydroxy deaconate (5-HD), a mito KATP channel blocker, significantly abolished the observed
IPC-induced cardioprotection in normal rat or daidzein and sodium nitrite perfused diabetic rat heart alone or in
combination.
Conclusions: Thus, it is suggested that attenuation of the cardioprotection in diabetic heart may be due to
decrease the IPC mediated release of NO in the diabetic myocardium, which may be due to up -regulation of
caveolin and subsequently decreased activity of eNOS.
Background
Ischemic heart disease is a leading cause of morbidity
and mortality worldwide [1]. Reperfusion of an ischemic
myocardium is a requisite, for the restoration of the
normal functioning of the myocardium [2]. However,
abrupt reperfusion of an ischemic myocardium is not
without hazard; it produces further damage of myocar-
dium, described as ischemia-reperfusion (I/R) injury
[3,4]. Moreover, it has been documented that “con-
trolled reperfusion” avoids further injury, both in myo-
cardium and in peripheral tissues [5-8]. Brief episodes of
ischemia followed by reperfusion of myocardium,
increase the resistance against sustained ischemia of
longer duration; this phenomenon is termed as ischemic
preconditioning (IPC) [9]. IPC produces cardioprotec-
tion by PI-3K/Akt [10,11], phosphorylation of eNOS
and by generation of nitric oxide (NO) and by opening
of mito KATP channel [12,13]. However, the cardiopro-
tective effect of IPC is attenuated in conditions such as
heart failure [14,15] aging [16,17] hypertension ([18,19]
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any medium, provided the original work is properly cited.obesity [20] hyperlipidemia [21-23]and diabetes mellitus
[24-26]. Diabetes mellitus is a one of the major risk fac-
tor for ischemic heart disease.
Caveolin is the caveolar membrane protein, invagi-
nated on the plasma membrane that serves as signalling
platform for many of the G-protein coupled receptors
(GPCR) [27-29]. IPC exerts cardioprotection by impair-
ing the death signalling components p38MAPKa and
JNK [30], by increase its association with caveolin. It has
been well documented that caveolin is a negative regula-
tor of eNOS, it interacts and inhibits the activity of
eNOS by making caveolin-eNOS complex [31,32]. IPC
increases the activity of eNOS by disrupting the com-
plex of caveolin and eNOS in rat heart [32]. Moreover,
it has been documented that NO produces cardioprotec-
tion by opening of KATP channel during IPC, and caveo-
lin facilitates the interaction of NO with KATP channel
by forming a suitable signaling platform [33]. Caveolin
maintains eNOS in inactivated state and thereby limits
NO production [34,35] and on agonist stimulation leads
to activation of eNOS through increased disruption of
caveolin/eNOS complex [31].
In diabetic rat heart, expression of caveolin increases
[36-38] which enhances the binding of eNOS to caveolin
and decreases the release of NO [31]. Therefore, the
present study was undertaken to elucidate whether or
not the diminished eNOS/NO signaling in diabetic myo-
cardium is responsible for loss of cardioprotective effect
of IPC.
Methods
The experimental protocol used in the present study
was approved by Institutional Animal Ethics Committee.
Drugs and chemicals
Daidzein (0.2 mg/Kg/s.c) (Sigma Aldrich [P] Ltd., Ban-
galore, India) was dissolved in dimethyl sulfoxide
(DMSO) and then injected to the animals for 7 days, 3
weeks after the administration of streptozotocin. Sodium
nitrite (10 μM/L) (Rankem, Fine Chemicals Ltd., New
Delhi, India) and 5-Hydroxy Decanoate (100 μM/L)
(Sigma Aldrich [P] Ltd., Bangalore, India) were added in
minimum quantity of distilled water and added to
Kreb’s Henseleit solution. All other reagents used in this
study were of analytical grade and always freshly pre-
pared before use.
Induction of experimental diabetes
Total 12 groups have been used in present study each
group consist of 6-10 Wistar rats (180-250) of either
sex. Experimental diabetes was induced by single dose
administration of streptozotocin (50 mg/kg, i.p)[ 3 9 ] .
There was 10% of mortality within 1
st week and 20%
mortality was noted up to harvesting of heart. Serum
glucose was estimated spectrophotometrically at 505 nm
by glucose oxidase/pyruvate oxidase (GOD-POD)
method [40,41] using an enzymatic kit (Kamineni Life
Sciences Pvt. Ltd. Hyderabad, India). Serum glucose
level > 200 mg/dl were considered to be hyperglycaemic.
Isolated rat heart preparation
Rats were administered heparin (500 IU/L, i.p) 20 min.
prior to sacrificing the animal by cervical dislocation.
Heart was rapidly excised and immediately mounted on
Langendorff’s apparatus [42]. Isolated heart was retro-
gradely perfused at constant pressure of 80 mmHg with
Kreb’s-Henseleit (KH) buffer (NaCl 118 mM; KCl 4.7
mM; CaCl2 2.5 mM; MgSO4.7H20 1.2 mM; KH2PO4
1.2 mM; C6H12O6 11 mM), pH 7.4, maintained at 37°C
bubbled with 95% O2 and 5%CO2. Flow rate was main-
tained at 7-9 ml/min. using Hoffman’s screw. The heart
was enclosed in double wall jacket, the temperature of
which was maintained by circulating water heated at 37°
C. Ischemic preconditioning was produced by closing
the inflow of K-H solution for 5 min followed by 5 min
of reperfusion. Four such episodes were employed. Glo-
bal ischemia was produced for 30 min. followed by 120
min. of reperfusion. Coronary effluent was collected
before ischemia, immediately, 5 min. and 30 min. after
reperfusion for estimation of Lactate Dehydrogenase
(LDH) and Creatine Kinase (CK-MB) [43].
Assessment of myocardial injury
The assessment of myocardial infarct size was done by
using triphenyltetrazolium chloride (TTC) staining
method, while LDH and CK-MB were estimated by
using commercially available kits (LDH Siemens Medical
Solution Diagnostics Ltd., Ajwa Road, Baroda, India,
CK-MB Nicholas Piramal India Ltd., Mumbai). Values
of LDH and CK-MB were expressed in international
units per litre (IU/L).
Assessment of myocardial infarct size
The heart was removed from the Langendorff’s appara-
tus. Both the atria and root of aorta were excised and
ventricles were kept overnight at -4°C temperature. Fro-
zen ventricles were sliced into uniform sections of about
1-2 mm thickness. The slices were incubated in 1% w/v
triphenyltetrazolium chloride stain (TTC stain) at 37°C
in 0.2 M Tris-chloride buffer for 30 min. The normal
myocardium was stained brick red while the infarcted
portion remained unstained. Infarct size was measured
by the volume method [44]
Nitrite estimation
Nitrite is a stable nitrogen intermediate formed from the
spontaneous degradation of NO. Unlike NO, nitrite can
be measured easily and nitrite concentrations can be
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release in coronary effluent was measured [48]. Greiss
reagent 0.5 ml (1:1 solution of 1% sulphanilamide in 5%
phosphoric acid and 0.1% N-(1-Naphthyl) ethylenedia-
mine dihydrochloride in water) was added to 0.5 ml of
coronary effluent. The optical density at 550 nm was
measured using spectrophotometer (UV-1700 Spectro-
photometer, Shimadzu, Japan). Nitrite concentration
was calculated by comparison with spectrophotometer
reading of standard solution of sodium nitrite prepared
in K-H buffer [48]
Experimental protocol
A diagrammatic representation of experimental protocol
is shown in Figure 1. In all groups, isolated rat heart was
perfused with K-H solution and allowed for 10 min of
stabilization. Group 1 (Sham Control; n = 6): Isolated rat
heart was perfused continuously for 200 min without
subjecting them to global ischemia and reperfusion.
Group 2 (Ischemia-Reperfusion Control; n = 6): After 10
min of stabilization, isolated rat heart preparation was
subjected to 30 min. global ischemia followed by 120
min. of reperfusion. Group 3 (Ischemic Preconditioning
Control; n = 6): After 10 min of stabilization, heart was
subjected to four cycles of ischemic preconditioning,
each cycle comprised of 5 min. global ischemia followed
by 5 min. reperfusion further followed by 30 min. global
ischemia and 120 min. of reperfusion. Group 4 (Ischemic
Preconditioning in Diabetic Rats; n = 6): Isolated heart
preparation from diabetic rat subjected to four cycles of
ischemic preconditioning as described earlier in group 3.
Group 5 (Ischemic Preconditioning in Daidzein (0.2 mg/
Kg/s.c/day) Pre-treated Diabetic Rat; n = 6): Isolated rat
heart preparation from daidzein (0.2 mg/Kg/s.c/day) pre-
treated diabetic rat was subjected to four cycles of
ischemic preconditioning as described earlier in group 3.
Group 6 (Ischemic preconditioning in Sodium Nitrite (10
μM/L) perfused Normal Rat Heart; n = 6): After 10 min
of stabilization, heart was perfused with K-H buffer con-
taining sodium nitrite (10 μM/L) for 30 min. and then
subjected to four cycles of ischemic preconditioning as
described earlier in group 3. Group 7 (Ischemic precon-
ditioning in Sodium Nitrite (10 μM/L) perfused Diabetic
Rat Heart; n = 6): Isolated heart preparation obtained
from diabetic rat was perfused with sodium nitrite (10
μM/L) for 30 min. followed by IPC as described in group
Group 1 (Sham Control) 
10’S 190’K-H
Group 2 ( Ischemia Reperfusion Control)
10’S 30’I 120’R
Group 4 (Ischemic Preconditioning in Diabetic Rat)
Group 3 (Ischemic Preconditioning  Control)
10’S 5’I 5’R
' 30’I 120’R
Group 5 (Ischemic Preconditioning  in Diadzein (0.2mg/Kg/s.c) Pre-treated Diabetic Rat)                  
Group 6 (Ischemic Preconditioning in Sodium Nitrite (10μM/L) Perfused Normal Rat Heart)
Group 7 (Ischemic Preconditioning  in Sodium Nitrite (10μM/L) Perfused Diabetic Rat Heart)
Group 8 (Ischemic Preconditioning in Diadzein (0.2mg/Kg/s.c) Pre- treated, Sodium Nitrite (10μM/L) Perfused Diabetic Rat Heart) 
Group 9 ( Ischemic Preconditioning  in 5-Hydroxy Decanoate (100μM/L) Perfused Normal Rat Heart)
Group 10 (Ischemic Preconditioning in 5-Hydroxy Decanoate (100μM/L) and Sodium Nitrite (10μM/L) Perfused Diabetic Rat Heart)
Group 11 (Ischemic Preconditioning in Diadzein (0.2mg/Kg/s.c) Pre-treated, 5-Hydroxy Decanoate (100μM/L) Perfused Diabetic
Rat Heart)
Group 12 (Ischemic Preconditioning in Diadzein (0.2mg/Kg/s.c) Pre-treated, 5-Hydroxy Decanoate (100μM/L) and Sodium
Nitrite (10μm/L) Perfused Diabetic Rat Heart).
10’S   10’P 30’P 5’I 5’R 30’I 120’R                                         
10’S   10’P 5’I 5’R 30’I 120’R
10’S   30’P 5’I 5’R 30’I 120’R
10’S   10’P 5’I 5’R 30’I 120’R
10’S 5’I 5’R
' 30’I 120’R
10’S 5’I 5’R
' 30’I 120’R
10’S   30’P 5’I 5’R 30’I 120’R
10’S   30’P 5’I 5’R 30’I 120’R
10’S   10’P 30’P 5’I 5’R 30’I 120’R                                         
Figure 1 Diagrammatic representation of experimental protocol. S, P, I, R, denotes stabilization, perfusion, ischemia and reperfusion
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mg/Kg/s.c/day) Pre-treated, Sodium Nitrite (10 μM/L)
Perfused Diabetic Rat Heart; n = 6): After 10 min of sta-
bilization, Isolated rat heart preparation from daidzein
(0.2 mg/Kg/s.c/day) pre-treated diabetic rat was perfused
with sodium nitrite (10 μM/L) for 30 min. followed by as
described in group 3. Group 9 (Ischemic Preconditioning
in 5-Hydroxy Decanoate (100 μM/L) Perfused Normal
Rat Heart; n = 6): After 10 min of stabilization, isolated
heart was perfused with K-H buffer containing 5-hydroxy
decanoate (100 μM/L) for 10 min. and then subjected to
IPC as described earlier in group 3. Group 10 (Ischemic
Preconditioning in Daidzein (0.2 mg/Kg/s.c/day) Pre-
treated, 5-Hydroxy Decanoate (100 μM/L) Perfused Dia-
betic Rat Heart; n = 6): After 10 min of stabilization, iso-
lated rat heart preparation from daidzein (0.2 mg/Kg/s.c/
day) pre-treated diabetic rat perfused with 5-hydroxy
decanoate (100 μM/L) containing K-H buffer for 10 min.
followed by as described in group 3. Group 11 (Ischemic
Preconditioning in 5-Hydroxy Decanoate (100 μM/L)
and Sodium Nitrite (10 μM/L) Perfused Diabetic Rat
Heart; n = 6): After 10 min of stabilization, isolated heart
preparation from diabetic rat was perfused with K-H buf-
fer containing 5-hydroxy decanoate (100 μM/L) for 10
min. which is further followed by perfusion with sodium
nitrite (10 μM/L) for 30 min. followed by as described
earlier in group 3. Group 12 (Ischemic Preconditioning
in Daidzein (0.2 mg/Kg/s.c/day) Pre-treated, 5-Hydroxy
Decanoate (100 μM / L )a n dS o d i u mN i t r i t e( 1 0μM/L)
Perfused Diabetic Rat Heart; n = 6): After 10 min of sta-
bilization, isolated rat heart preparation from daidzein
(0.2 mg/Kg/s.c/day) treated diabetic rat was followedby
group 11.
Statistical analysis
All values were expressed as mean ± standard deviation
(S.D). Statistical analysis was performed using Sigmastat
Software. Glucose value was compared by Student’s
paired t-test. The values of infarct size, LDH, CK-MB
and nitrite level were statistically analysed using one-
w a ya n a l y s i so fv a r i a n c e( A N O V A )f o l l o w e db yT u k e y ’s
multiple comparison test as a post hoc test. Value of P
< 0.05 was considered to be statistically significant.
Results
Effect of streptozotocin on serum glucose
The administration of single dose of streptozotocin (50
mg/Kg, i.p) significantly increased blood glucose as com-
pared to basal value (Figure 2).
Effect of ischemic preconditioning and pharmacological
interventions on myocardial infarct size
Global ischemia for 30 min followed by 120 min of
reperfusion significantly increased the myocardial
infarct size, as compared to sham control. Four epi-
sodes of IPC significantly decreased I/R induced
increase in myocardial infarct size in normal rat heart.
However, ischemic preconditioning failed to decrease
the myocardial infarct size in diabetic rat heart. More-
over, IPC induced decrease of infarct size was signifi-
cantly restored in DDZ pre-treated and in sodium
nitrite perfused diabetic rat heart. However, perfusion
with 5-HD significantly attenuated the decrease of
myocardial infarct size in normal, DDZ pre-treated
and sodium nitrite perfused diabetic rat heart alone or
in combination (Figure 3).
Effect of ischaemic preconditioning and pharmacological
interventions on the release of Lactate dehydrogenase
(LDH)
Global ischemia for 30 min followed by 120 min of
reperfusion markedly increased the release of LDH as
compared to sham control. Four episodes of IPC signifi-
cantly reduced the I/R induced increase in the release of
LDH in normal rat heart but not in the diabetic rat
heart. Moreover, IPC induced decrease in the release of
LDH was significantly restored in DDZ pre-treated, and
in sodium nitrite perfused diabetic rat heart. However,
perfusion with 5-HD significantly attenuated the
decrease in the release of LDH in normal, DDZ pre-
treated and sodium nitrite perfused diabetic rat heart
alone or in combination (Figure 4).
Effect of ischemic preconditioning and pharmacological
interventions on the release of CK-MB
Global ischemia for 30 min followed by 120 min of
reperfusion markedly increased the release of CK-
M B ,a sc o m p a r e dt os h a mc o n t r o l .F o u re p i s o d e so f
IPC significantly reduced the I/R induced increase in
the release of CK-MB in normal rat heart but not in
the diabetic rat heart. Moreover, IPC induced
decrease release of CK-MB was significantly restored
in DDZ pre-treated and sodium nitrite perfused dia-
betic rat heart. However, perfusion with 5-HD signifi-
cantly attenuated the decrease in the release of CK-
MB in normal, DDZ pre-treated and sodium nitrite
perfused diabetic rat heart alone or in combination
(Figure 5).
Effect of ischemic preconditioning and treatment with
daidzein on the release of nitrite
Four episodes of IPC significantly increased the release
of nitrite into coronary effluent of normal animals, as
compared to I/R group but not in isolated heart
obtained from diabetic rat. Treatment with daidzein, a
caveolin inhibitor (0.2 mg/Kg/s.c, one week), signifi-
cantly increased, the release of nitrite in diabetic rat
heart subjected to IPC (Figure 6).
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Four episodes of 5 min ischemia followed by reperfusion
for 5 min, effectively preconditioned the normal rat
heart as indicated by a significant decrease in infarct
size and ischemia-reperfusion induced release of LDH
and CK-MB. This cardioprotective effect of ischemic
preconditioning is in agreement with earlier studies
[49-51]. However the cardioprotective effect of ischemic
preconditioning was significantly attenuated in diabetic
rat heart. Our result is supported by earlier published
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Figure 2 Effect of streptozotocin administration on serum glucose in the rat. Values are expressed as mean ± S.D. * = p < 0.05 vs. Control
animals.
Figure 3 Effect of I-R on myocardial infarct size, effect of ischemic preconditioning (IPC) on myocardial infarct size in normal and
diabetic rat heart, effect of DDZ pre-treatment, sodium nitrite perfusion on myocardial infarct size in diabetic rat heart and effect of
5-HD alone or in combination with DDZ and sodium nitrite on myocardial infarct size in diabetic rat heart. I/R, IPC, DM, DDZ, 5-HD
denotes ischemia reperfusion, ischemic preconditioning, diabetes mellitus, daidzein and 5-hydroxy decanoate respectively. Values are expressed
as mean ± S.D, a = p < 0.05 vs. sham control; b = p < 0.05 vs. I/R Control; c = p < 0.05 vs .IPC in diabetic rat heart; d = p < 0.05 vs. IPC in
normal rat heart; e = P < 0.05 vs. IPC in DDZ pretreated diabetic rat heart; f = p < 0.05 vs. IPC in sodium nitrite perfused diabetic rat heart; g =
p < 0.05 vs. IPC in DDZ pretreated, sodium nitrite perfused diabetic rat heart.
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Page 5 of 10Figure 4 Effect of I-R on the release of LDH, effect of ischemic preconditioning (IPC) on the release of LDH in normal and diabetic rat
heart, effect of DDZ pre-treatment, sodium nitrite perfusion on the release of LDH in diabetic rat heart and effect of 5-HD alone or in
combination with DDZ and sodium nitrite on the release of LDH in diabetic rat heart. I/R, IPC, DM, DDZ, 5-HD denotes ischemia
reperfusion, ischemic preconditioning, diabetes mellitus, daidzein and 5-hydroxy decanoate respectively. Values are expressed as mean ± S.D,
a = p < 0.05 vs. sham control; b = p < 0.05 vs. I/R Control; c = p < 0.05 vs. IPC in diabetic rat heart; d = p < 0.05 vs. IPC in normal rat heart;
e = P < 0.05 vs. IPC in DDZ pretreated diabetic rat heart; f = p < 0.05 vs. IPC in sodium nitrite perfused diabetic rat heart; g = p < 0.05 vs. IPC
in DDZ pretreated, sodium nitrite perfused diabetic rat heart.
Figure 5 Effect of I-R on the release of CK-MB, effect of ischemic preconditioning (IPC) on the release of CK-MB in normal and
diabetic rat heart, effect of DDZ pre-treatment, sodium nitrite perfusion on the release of CK-MB in diabetic rat heart and effect of 5-
HD alone or in combination with DDZ and sodium nitrite on the release of CK-MB in diabetic rat heart. I/R, IPC, DM, DDZ, 5-HD denotes
ischemia reperfusion, ischemic preconditioning, diabetes mellitus, daidzein and 5-hydroxy decanoate respectively. Values are expressed as mean
± S.D, a = p < 0.05 vs. sham control; b = p < 0.05 vs. I/R Control; c = p < 0.05 vs .IPC in diabetic rat heart; d = p < 0.05 vs. IPC in normal rat
heart; e = P < 0.05 vs. IPC in DDZ pretreated diabetic rat heart; f = p < 0.05 vs. IPC in sodium nitrite perfused diabetic rat heart; g = p < 0.05 vs.
IPC in DDZ pretreated, sodium nitrite perfused diabetic rat heart.
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Page 6 of 10studies [52-54,22,23]. It has been reported that perfusion
of sodium nitrite produces cardioprotection in isolated
heart from normal rat, subjected to global ischemia
[55,56]. In our study, perfusion of sodium nitrite (a pre-
cursor of NO) [56] followed by IPC, significantly restored
the attenuated effect of IPC in the diabetic myocardium
(decreases in infarct size and in the release of LDH and
CK-MB in coronary effluents). It is probable that the
attenuated cardioprotective effect of IPC in diabetic rat
may be due to decreased availability of NO. Thus, NO
appears to be responsible for cardioprotective effect of
ischemic preconditioning [13]. However, in our study,
treatment with sodium nitrite did not enhance the cardi-
oprotective effect of IPC in normal rat. This indicates
that once IPC mediated increased generation of NO
achieved the threshold for cardioprotection and the addi-
tion of sodium nitrite (NO donor) [56] was unable to
further increase the myocardial protection by IPC, per se.
Opening of mitochondrial ATP sensitive potassium
channels (mito KATP channels) protects the myocardium
from ischemia-reperfusion induced injury [57]. Various
mediators i.e. adenosine, bradykinin, angiotensin, prosta-
glandins and NO which are released by the stimuli of
IPC produce cardioprotection through opening of mito
KATP channel [58,59]. Further, administration of 5-HD,
am i t o K ATP channel blocker, attenuated the observed
cardioprotective effect of IPC in normal rat heart and in
the sodium nitrite perfused diabetic rat heart. It is sug-
gested that the observed cardioprotective effect of IPC
in normal rat and sodium nitrite perfused diabetic rat-
m a yb ed u et oo p e n i n go fm i t oK ATP channel. Our
results are in accordance with reports from other
laboratories [60,61].
Caveolins are proteins that form the structure of
caveolar membrane, act as a signaling platform (signalo-
somes) for molecules such as nitric oxide synthase
(NOS) and Src-like kinases and many of the G-proteins
coupled receptors (GPCR) [27-29]. Ischemic precondi-
tioning can modulate the microenvironment of caveolin
and promote the signalling involved in protection of
myocardium against ischemia-reperfusion induced injury
[62]. It has been reported that expression of caveolin is
upregulated in diabetic myocardium [37,38]. Caveolin is
known to be a negative regulator of NO, it maintains
eNOS in inactivated state by making caveolin-eNOS
complex [36] and on agonist stimulation leads to activa-
tion of eNOS and increased release of NO; by disrupting
caveolin/eNOS complex [31]. Increased expression of
caveolin may lead to the increased interaction with
eNOS, decreasing it’s phosphorylation and a consequent
decrease in the generation of NO [63]. In our study,
IPC-induced release of nitrite in diabetic rat was signifi-
cantly decreased as compared to normal rat. Our finding
is supported by other reports that the decreased release
of NO in the diabetic rat heart, is due to decreased
activity of eNOS by an upregulation of caveolin in the
myocardium [36,38].
Treatment with daidzein, has been noted to inhibit the
expression of a caveolin in the diabetic rat [64,65]. In
the present study daidzein treatment for seven days,
three weeks after the administration of STZ, followed by
IPC; significantly restored the cardioprotective effect in
diabetic rat heart and increased the release of NO, with-
out affecting the serum glucose. In normal heart, IPC
leads to increased expression of caveolae [66]. Each brief
episode of coronary occlusion produces small bursts of
reactive oxygen species (ROS), and leads to increased
formation and release of NO, by cleaving the caveolin-
eNOS complex. Furthermore, antioxidants have been
demonstrated to abolish IPC-induced cardiac protection
in normal heart (62,67,68). Why IPC-induced cardiac
protection is lost in diabetic heart is not known?.
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Figure 6 Effect of ischemic preconditioning (IPC) and treatment of DDZ, on the release of nitric oxice in diabetic rat heart. I/R, IPC, DM,
DDZ, denotes ischemia reperfusion, ischemic preconditioning, diabetes mellitus and daidzein respectively. Values are expressed as mean ± S.D, a
= p < 0.05 vs. I/R Control; b = p < 0.05 vs .IPC in diabetic rat heart.
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tion by daidzein pre-treatment indicates that some
defect in caveolin-eNOS complex may be involved in
this process, as indicated in our study by a decrease in
release of nitrite in the coronary effluent in the diabetic
heart and its significant attenuation by daidzein pre-
treatment. Roth and Patel (69) demonstrated that inter-
action of signalling molecules with caveolae is necessary
for cardiac protection. The results obtained in our study
support this viewpoint.
In the present study, we have used daidzein as an
inhibitor of expression of caveolin in male as well as
female rats. A limitation of daidzein, is that being a phy-
toesterogen it may modulate the estrogens status in
female animals. However, in an earlier study, no signifi-
cant difference in the effect of daidzein was detected
between male and female rats (data not shown). Also,
the restoration of the cardioprotective effect of IPC in
diabetic rat heart by combination of daidzein and
sodium nitrite was not greater than that observed when
these drugs were used alone, suggesting thereby that
these two drugs act by the same mechanism i.e., NO
pathway.
Conclusions
On the basis of above discussion, it may be concluded
that attenuation of cardioprotective effect of ischemic
preconditioning in diabetic rat heart is due to some
defect in caveolin-eNOS complex in diabetic heart,
which leads to, a decrease in the availability of NO and
the consequent decreased activation of mito KATP chan-
nels. Also, the IPC-induced changes in eNOS and NO
in daidzein pre-treated diabetic heart, closely mimic
those produced by IPC in the non-diseased heart.
Limitation of the present study
Ideally, the proposed caveolin-eNOS interaction should
have been assessed by coimmunoprecipitation study or
by caveolin isolation.
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